Overall market sentiment has been high on Hepion Pharmaceuticals Inc (HEPA) stock lately. HEPA receives a Bullish rating from InvestorsObserver's Stock Sentiment Indicator.
What is Stock Sentiment?
Sentiment uses short term technical analysis to gauge whether a stock is desired by investors. As a technical indicator, it focuses on recent trends as opposed to the long term health of the underlying company. Updates for the company such as a earnings release can move the stock away from current trends.
Recent trends are a good indator of current market sentiments. In its most basic form, stocks that are trending up are desirable by investors while stocks currently falling must be unattractive.
InvestorsObserver's Sentimental Indicator tracks both changes in price and volume to analyze the most recent trends. Typically an increase in volume indicates ongoing trends are getting stronger, while a decrease in volume usually signals an end to the current trend.
Available options can also represent current sentiments for a given stock. Since investors are able to bet on future trends of stocks using options, we consider the ratio of calls to puts when analyzing market sentiments .
What's Happening With HEPA Stock Today?
Hepion Pharmaceuticals Inc (HEPA) stock is down -9.83% while the S&P 500 is up 0.57% as of 11:04 AM on Wednesday, Jul 8. HEPA has fallen -$0.40 from the previous closing price of $4.12 on volume of 1,620,363 shares. Over the past year the S&P 500 is higher by 6.30% while HEPA has fallen -3.63%. HEPA lost -$9.51 per share in the over the last 12 months.
To screen for more stocks like Hepion Pharmaceuticals Inc click here.
More About Hepion Pharmaceuticals Inc
Hepion Pharmaceuticals Inc is a United States-based biopharmaceutical company engaged in the development of targeted pharmaceutical therapies for liver disease. This therapeutic approach targets fibrosis and hepatocellular carcinoma associated with non-alcoholic steatohepatitis, viral hepatitis, and other liver diseases. The company's cyclophilin inhibitor, CRV431 targets multiple biochemical pathways involved in the progression of liver disease.
